{"id":46537,"date":"2021-09-01T16:43:44","date_gmt":"2021-09-01T15:43:44","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/long-term-results-of-autologous-plasma-as-adjuvant-to-pars-plana-vitrectomy-in-the-treatment-of-high-myopic-full-thickness-macular-holes\/"},"modified":"2026-02-26T17:35:00","modified_gmt":"2026-02-26T16:35:00","slug":"long-term-results-of-autologous-plasma-as-adjuvant-to-pars-plana-vitrectomy-in-the-treatment-of-high-myopic-full-thickness-macular-holes","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/it\/long-term-results-of-autologous-plasma-as-adjuvant-to-pars-plana-vitrectomy-in-the-treatment-of-high-myopic-full-thickness-macular-holes\/","title":{"rendered":"Long-term results of autologous plasma as adjuvant to pars plana vitrectomy in the treatment of high myopic full-thickness macular holes"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text css=””]<\/p>\n

Abstract<\/h3>\n
\n
\n

Background:\u00a0<\/strong>To analyse the feasibility and efficacy of a novel autologous plasma rich in growth factor (PRGF) preparation as adjuvant to pars plana vitrectomy and internal limiting membrane peel in high myopic full-thickness macular hole (FTMH).<\/p>\n

Methods:\u00a0<\/strong>Single-centre, single-surgeon retrospective chart review of consecutive patients with high myopic FTMH who underwent surgery with a minimum follow-up of 12 months. Patients were divided in group 1 (na\u00efve) and group 2 (persistent). Quantitative and qualitative variables were analysed, compared among groups and correlated with best corrected visual acuity (BCVA).<\/p>\n

Results:\u00a0<\/strong>Postoperatively, FTMH resolved in 28\/31 eyes in group 1 (90%) and in 10\/11 eyes in group 2 (91%), without significant differences (p = 0.954). None of the preoperative anatomical variables analysed showed significant association with preoperative BCVA. Intraoperatively, no significant complications were registered. Postoperatively, BCVA improved significantly in the studied population (p < 0.001). Preoperative factors associated with better postoperative BCVA were the presence of intraretinal cystoid spaces (p = 0.028) and elevated FTMH borders (p = 0.005). Preoperative dome-shaped macula was associated with significantly worse postoperative BCVA (p = 0.049).<\/p>\n

Conclusions:\u00a0<\/strong>The use of PRGF as adjuvant to vitrectomy showed to be reproducible, straightforward and efficient, with primary anatomical success rate comparable to other surgical approaches and lower risk of complications.<\/p>\n<\/div>\n

Keywords:\u00a0<\/strong>Pars plana vitrectomy; epiretinal membrane; macular hole; pathologic myopia; retina; vitreous traction syndromes; vitreous\/endophthalmitis.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row][vc_column]\n Accedi all'articolo completo<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Eur J Ophthalmol. 2021 Sep;31(5):2612-2620.<\/strong>
\nTo analyse the feasibility and efficacy of a novel autologous plasma rich in growth factor (PRGF) preparation as adjuvant to pars plana vitrectomy and internal limiting membrane peel in high myopic full-thickness macular hole (FTMH).<\/p>\n","protected":false},"author":2002,"featured_media":46523,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157],"tags":[],"class_list":["post-46537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-rigenerativa"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/46537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/comments?post=46537"}],"version-history":[{"count":1,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/46537\/revisions"}],"predecessor-version":[{"id":46538,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/46537\/revisions\/46538"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media\/46523"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media?parent=46537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/categories?post=46537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/tags?post=46537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}